Moffitt Cancer Center Logo
 

Hussain I. Saba, MD, PhD

Where You Are:

Hussain I. Saba, MD, PhD

Medical Oncology

For Consultation Requests or Referrals: (813) 745-8470

 
 

BOARD CERTIFICATION:

FELLOWSHIP:
          •  University of North Carolina School of Medicine, Chapel Hill - Hematology/Oncology

RESIDENCY:
          •  University of North Carolina School of Medicine - Medicine

MEDICAL SCHOOL:
          •  Darrbhanga Medical College, Bihar University, India - MD

  • Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct;120(17):3419-3424. Pubmedid: 22936658.

  • Saba HI, Tran DQ. Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors. J Blood Med. 2012 Aug;3:17-23. Pubmedid: 22715320. Pmcid: PMC3370834.

  • Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Ganetsky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP, Maciejewski JP. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010 May;28(13):2253-2258. Pubmedid: 20354132. Pmcid: PMC2860439.

  • Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb;28(4):605-613. Pubmedid: 20038729. Pmcid: PMC2815995.

  • Saba HI, Morelli GA, Saba RI. Disseminated Intravascular Coagulation (DIC) in Cancer. Cancer Treat Res. 2009;148:137-156. Pubmedid: 19377923.

  • Wijermans PW, R?ter B, Baer MR, Slack JL, Saba HI, L?bbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-591. Pubmedid: 17881052.

  • Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007 Oct;3(5):807-817. Pubmedid: 18473005. Pmcid: PMC2376088.

  • Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan;109(1):52-57. Pubmedid: 16882708.

  • Aledort L, Hayward C, Chen M, Nichol J, Bussel J, Saba H. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet count, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. J Clin Oncol. 2004;22(3):3218-3228. Pubmedid: 15224353.

  • McIlwain L, Sokol L, Moscinski L, Saba H. Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol. 2003 Apr;70(4):242-245. Pubmedid: 12656749.

  • Saba HI, Morelli GA, Azam RR, Klein CJ, Letson GD. Efficacy of NovoSeven during surgery on a haemophiliac with previous history of inhibitors. Haemophilia. 2003 Jan;9(1):131-136. Pubmedid: 12558792.

  • Saba H, Khalil F, Morelli G, Foulis P. Thromboembolism preceding cancer: A correlation study. Am J Hematol. 2003;72:109-114. Pubmedid: 12555214.

  • Saba H. Myelodysplastic syndromes in the elderly. Cancer Control. 2001;8(1):79-102. Pubmedid: 11176039.

  • Kerr DS, Briggs DM, Saba HI. A neurophysiological method of rapid detection and analysis of marine algal toxins. Toxicon. 1999 Dec;37(12):1803-1825. Pubmedid: 10519657.

  • Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999 Feb;93(3):787-795. Pubmedid: 9920827.

  • Benson K, Agosti S, Lyman G, Pow-Sang J, Saba H, Balducci L. Estimated blood loss in group O as compared to non-group O radical prostatectomy. Hematology. 1998;3:257-261. Pubmedid: noPMID.

  • Ballester O, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A, Kronish L, Sullivan P, Elfenbein G. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Brit J Haematol. 1997 Mar;96(4):746-748. Pubmedid: 9074417.

  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic Seminoma Simulating Malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1996;23:165-171. Pubmedid: 9021701.

  • Saba H. The role of growth factors in management. Leuk Res. 1996;30(3):203-217. Pubmedid: 8637215.

  • Saba H, Spiers A, Greene J, Alkan S. Hematological effects of human immunodeficiency virus infection. Cancer Control. 1995;2(2):104-112. Pubmedid: 10887019.

  • Saba H. A brief history of hemophilia. In: Home healthcare consultant (proceedings of "Integrating hemophilia care and managed care: a conferance for case managers. 1995;8-10.

  • Spiers A, Saba H, Ballester O, Moscinski L, Morgan M, Williams E. Purple people with lymphoid neoplasms: a new clinical andpathological syndrome. Hematol Rev. 1995;9:197-204. Pubmedid: noPMID.

  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic seminoma simulating malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1995;18:179-184. Pubmedid: noPMID.

  • Saba H. Hematological complications of acquired immune deficiency syndrome. Hematol Rev. 1994;8:225-229.

  • Saba H, Spiers A. Hematological manifestations of acquired immune deficiency syndrome: current understanding and management. Hematol Rev Commun. 1994;9:51-69.

  • Saba H, Morelli G, Logrono L. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasis with epsilon aminocaproic acide. N Engl J Med. 1994;330:1789-1790.

  • Ballester O, Agaliotis D, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A. 1994;209.

  • Saba H, Nawab U, Nadeem S, Cosgrove D, Moscinski L, Spiers A, Balducci L, Lyman G, Zuckerman K. 1994;624a.

  • Ballester O, Moscinski L, Lyman G, Chaney J, Saba H, Spiers A, Klein C. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood. 1994;83(7):1903-1908.

  • Spiers A, Saba H, Vieson K, Ballester O, Moscinski L, Dinwoodie W. Mycosis fungoides and Sezary syndrome: treatment with carboplatin and etoposide by continuous intravenous infusion. Blood. 1994;84:169a-169a.

  • Rabb H, Mendiola C, Dietz J, Saba H, Issekutz T, Abanilla F, Bonventre J, Ramirez G. Role of CD11a & CD11b in ischemic acute renal failure in rats. Am J Physiol. 1994;267:F1052-1058.

  • Mehta P, Saba H, Bayer P, Davis J. Emergency room care for hemophiliac patients: understanding and overcoming difficulties. J Fla Med Assoc. 1993;80(4):250-254.

  • Virgilio J, Moscinski L, Ballester O, Corrado C, Guida C, Balducci L, Saba H. Acute lymphoblastic leukemia (ALL) in elderly patients. Hematol Oncol. 1993;11(3):121-126.

  • Reintgen D, Cruse C, Schroer K, Glass L, Saba H, Puleo C, King J, Berman C, Hannon L, Cox C. Computer database for melanoma: a clinical management and research tool to ensure continuous quality assessment. Semin Surg Oncol. 1993;9:208-214.

  • Edwards T, Nelson R, Ballester O, Saba H, Lockey R. Polycythemia as a complication of human immunodeficiency virus infection. South Med J. 1993;86(6):686-688.

  • Saba H. Blood coagulation and fibrinolysis: an overview. Hematol Rev. 1993;7:225-230.

  • Reintgen D, Saba H. Chemotherapy for stage 4 melanoma: a three year experience with DTIC, BCNU, cisplatin and tamoxifen. Semin Surg Oncol. 1993;9:251-255.

  • Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey. Blood. 1993;82:2245-2245.

  • Garland L, Cadigan B, Ballester O, Saba H. Acquired factor VIII deficiency and polyradiculoneuropathy. N Engl J Med. 1992;324:1139-1139.

  • Ballester O, Saba H, Moscinski L, Nelson R, Foulis P. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol. 1992;29:106-108.

  • Saba H, Ballester O, Balducci L. Hemopoietic growth factors in myelodysplasia. Hematol Rev. 1992;5:207-221.

  • Reintgen D, Cruse C, Wells K, Saba H, Fabri P. The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg. 1992;28:55-59.

  • Ballester O, Saba H. Role of growth factors in the management of non-malignant hemopoietic failure. Hematol Rev. 1992;5:223-227.

  • Saba H, Cruse C, Wells K, Klein C, Wood H, Reintgen D. Adjuvant chemotherapy in malignant melanoma using DTIC, BCNU, cisplatin and tamoxifen. Ann Plast Surg. 1992;28:60-65.

  • Flannery M, Simmons D, Saba H, Altus P, Wallach P, Adelman H. Fluconazole in the treatment of hepato-splenic candidiasis. Arch Intern Med. 1992;152:406-408.

  • Reintgen D, Cruse C, Wells K, Stankard C, Saba H, Schroer K, Cox C, Berman C, Glass L, Alvarez L, Brozena S, Fenske N, Fabri P. The effectiveness of skin cancer screening and continuing education programs toward increasing the survival of patients with malignant melanoma. Surg Oncol. 1992;1:379-384.

  • Ballester O, Wang T, Saba H, Morelli G, Tantranond O, Balducci L. Classic hemophilia in elderly patients. J Am Geriatr Soc. 1992;40(8):824-826.

  • Norman Jr. J, Cruse C, Wells K, Saba H, Reintgen D. Metastatic melanoma with an unknown primary. Ann Plast Surg. 1992;28(1):81-84.

  • Mehta P, Saba H, Lian E, Davis J, Cumming W, Barrett D, Sandler E, Kalen V, Kao K, Reiter W. Guildelines for hemophilia care. J Fla Med Assoc. 1992;78(4):222-224.

  • Saba H, Cruse C, Wells K, Klein C, Reintgen D. Malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt melanoma center study. Ann Plast Surg. 1992;28(1):65-69.

  • Ballester O, Moscinski L, Lyman G, Chaney J, Saba H, Spiers A, Klein C. Interleukin-6: a growth factor or a differentiation factor for multiple myeloma. Blood. 1992;80:483-483.

  • Reintgen D, Cruse C, Wells K, Saba H, Slingluff. Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg. 1992;28:50-54.

  • O'Brien WF, Knuppel RA, Saba HI, Angel JL, Benoit R, Bruce A. Serum prostacyclin binding and half-life in normal and hypertensive pregnant women. Obstet Gynecol. 1989 Jan;73(1):43-46. Pubmedid: 2642327.

  • Saba SR, Saba HI. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism. Am J Hematol. 1985 Oct;20(2):97-105. Pubmedid: 3898823.

  • Saba HI, Saba SR, Morelli G, Hartmann RC. Endotoxin-mediated inhibition of human platelet aggregation. Thromb Res. 1984 Apr;34(1):19-33. Pubmedid: 6328692.

  • Saba HI, Saba SR, Blackburn CA, Hartmann RC, Mason RG. Heparin neutralization of PGI2: effects upon platelets. Science. 1979 Aug;205(4405):499-501. Pubmedid: 377493.

  • Lyman GH, Hartmann RC, Saba HI, Preston D, Shukovsky L, Jensen R, Knight M. Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma. South Med J. 1978 May;71(5):519-24, 529. Pubmedid: 644360.

  • Saba HI, Herion JC, Walker RI, Roberts HR. Effect of lysosomal cationic proteins from polymorphonuclear leukocytes upon the fibrinogen and fibrinolysis system. Thromb Res. 1975 Oct;7(4):543-554. Pubmedid: 811.

Myelodysplastic syndrome; acute and chronic leukemias, non-Hodgkin lymphomas; hemostasis; hemophilia & Von Willebrand disease